Cardiovascular events resulting from long-term, high-dosage use of selective cyclooxygenase 2 (COX-2) inhibitors, or coxibs, are linked to a surge in blood levels of a metabolite that is a potent vasoconstrictor and that increases platelet aggregation and clot formation, reported scientists at the University of California, Davis, and Beijing University in China (Liu J-Y et al. Proc Natl Acad Sci U S A.
doi:10.1073/pnas.1011278107 [published online September 13, 2010]).
Friedrich MJ. Cardiovascular Risk from Coxibs. JAMA. 2010;304(17):1888. doi:10.1001/jama.2010.1520